Eli the donkey provides another example from the animal world of the success of adult stem cells. On May 13, 2010 Eli was attacked by a stablemate twice his size. The trauma led to swelling of his spinal cord, and rapid progression of weakness in his front end and hindquarters. The veterinarians treating Eli also got the opinion of Dr. Mike Kistler of Cortez, Colorado, a senior member of the American Society of Neuroradiology with more than 25 years of experience in human spinal trauma.
Newswise — The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.
Considering the spleen’s role in the after-effects of spinal cord injury could change the way researchers pursue potential treatments for these devastating injuries.
Newswise — If researchers could determine how to send signals to cells responding to a spinal cord injury, they might be able to stop one type of cell from doing additional damage at the injury site and instead, coax it into helping nerve cells grow.
Eli the donkey’s recovery from incomplete quadriplegia could be the most important breakthrough in traumatic spinal-cord injuries and for the stem-cell treatment that restored his mobility—a breakthrough that could impact not only equids but all mammals, including humans.
Quadriplegia is considered incomplete if there is lack of mobility yet some sensory or motor function below the affected area.
On May 13, little Eli was inexplicably savaged by his longtime companion Watson, a jack nearly twice his size.
(Reuters) – StemCells Inc has filed for Swiss regulatory approval for the first clinical trial of its nerve stem cells in patients with spinal cord injuries as much as a year old, the company said.
It expects to enroll about a dozen patients whose injuries are between three and 12 months old.
“To date, the focus has been on the acute spinal cord injury phase,” StemCells CEO Martin McGlynn said in a telephone interview. “That’s an important area to address, but the largest unmet need is those who have passed that immediate acute phase of injury.”
Newswise — A study led by researchers in the Department of Neurosciences at the University of California, San Diego School of Medicine shows unexpected and extensive natural recovery after spinal cord injury in primates. The findings, to be published November 14 in the advance online edition of Nature Neuroscience, may one day lead to the development of new treatments for patients with spinal cord injuries.
While regeneration after severe brain and spinal cord injury is limited, milder injuries are often followed by good functional recovery.
clinical trial in Atlanta, Georgia, is proof that informed public debate is the key to medical advance
IF I’m honest, my first reaction to recent reports that the first human embryonic stem cell trial had begun on spinal patients in Atlanta was one of nonchalance.
Not because of its potential significance to those of us with spinal injuries — desperate for any news of progress — but because of the stop-start nature of the trial, plagued as it has been by legislative and regulatory restraints.
Millions of people worldwide experience spinal cord injuries. Breakthroughs bring researchers progress, but a complete cure is a long way off
Spinal cord repair focuses on finding ways to make axons regrow and connect properly, replace damaged neurons, protect surviving neurons from further injury and retrain neural circuits to repair body functions.
The use of a hydrophilic-coated catheter called SpeediCath (Coloplast) delays the onset of urinary tract infections (UTIs) in patients with acute spinal cord injury.
Compared with the use of an uncoated polyvinyl chloride catheter, SpeediCath significantly delayed the time to first UTI in individuals with a recent spinal cord injury (SCI), study findings suggest. The daily risk of experiencing the first UTI was decreased by 50%. Use of the Speedicath hydrophilic coasted catheter reduced the number of UTIs per month by 21% in the acute care period.
Oct. 11 (Bloomberg) — Geron Corp. used a therapy made from stem cells taken from human embryos to treat a patient paralyzed by a spinal-cord injury in the first U.S.-authorized test of the technology.
The patient was treated Oct. 8 at Shepherd Center, a rehabilitation hospital in Atlanta, the company said today in a statement. The study is designed to test the safety of Geron’s therapy in patients with spinal cord injuries. The U.S. Food and Drug Administration gave permission in July for Geron to start the study after a halt of almost a year over safety concerns.